@misc{oai:repo.qst.go.jp:00074791,
 author = {Helm, Alexander and ティンガネリ, ワルター and Simoniello, Palma and Bisio, Alessandra and Marchesano, Valentina and 黒澤, ふき and エブナー, ダニエル and Durante, Marco and 下川, 卓志 and Tinganelli, Walter and Kurosawa, Fuki and Ebner, Daniel and Shimokawa, Takashi},
 month = {Sep},
 note = {Background
Combination radiotherapy and immunotherapy shows highly promising clinical results and is therefore a regimen of growing interest. Ionizing radiation is reported to be immunogenic, i.e. it may induce an immunogenic cell death in tumor cells leading to immunoactivation, in turn resulting in the shrinkage of out-of-field metastases. This phenomenon is termed the abscopal effect. Particle therapy with protons and especially carbon-ions is assumed to further increase the immunogenic effect.
Brief methods
We set up a combination of particle radiation (carbon ions or protons) together with Ipilimumab and/or Nivolumab before or after exposure, so as to enhance the abscopal effect in mouse models (C3H/He and C57BL/6) harboring tumors originating from B16 melanoma cells and LM8 osteosarcoma, respectively.
Results
In a C57BL/6-B16 model, a combination of carbon ion therapy and Ipilimumab/Nivolumab tended to result in a reduced growth of abscopal tumors in comparison with carbon ions or Ipilimumab/Nivolumab only. In a C3H/He-LM8 model, the combination of carbon ion therapy and Ipilimumab/Nivolumab resulted in a reduced growth of the abscopal tumor and reduced formation of lung metastases.
Conclusions
The model seems suitable to study the optimal temporally application of drugs in combination with radiation. Further experiments are currently under analysis. Here we present our group's first results., the 3th international conference of Immunotherapy Radiotherapy combinations},
 title = {Combination immunotherapy-radiation therapy using particles with Ipilimumab and Nivolumab in mouse models},
 year = {2018}
}